Abstract
The authors conducted a pilot randomized, double-blind, placebo-controlled clinical trial of the transdermal administration of selegiline in HIV+ patients to obtain preliminary data to assess its safety, tolerability, and impact on HIV-associated cognitive impairment. Both selegiline and placebo were well tolerated with few adverse events. Improvements favoring the selegiline group were suggested on single tests of verbal memory and motor/psychomotor performance, warranting a larger study.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Administration, Cutaneous
-
Adult
-
Cognition Disorders / virology*
-
Female
-
HIV Seropositivity / physiopathology
-
HIV Seropositivity / psychology*
-
Humans
-
Male
-
Mental Recall / drug effects
-
Middle Aged
-
Monoamine Oxidase Inhibitors / administration & dosage*
-
Monoamine Oxidase Inhibitors / adverse effects
-
Monoamine Oxidase Inhibitors / therapeutic use
-
Motor Activity / drug effects
-
Pilot Projects
-
Placebos
-
Psychomotor Performance / drug effects
-
Selegiline / administration & dosage*
-
Selegiline / adverse effects
-
Selegiline / therapeutic use
-
Verbal Learning
Substances
-
Monoamine Oxidase Inhibitors
-
Placebos
-
Selegiline